Rifampicin and Trimethoprim\Sulfamethoxazole plus intralesional antimony compared with antimony alone in treatment of cutaneous leishmaniasis.
|
|
Author:
|
AHMED KAWEN, DR. WISAM MAJEED KATTOOF
|
Abstract:
|
The present study was conducted to evaluate the efficacy of Rifampicin and Trimethoprim plus sodium stibogluconate
antimony and sodium stibogluconate antimony in treatment of cutaneous leishmaniasis. This study was carried out on
89 patients were enrolled in the study and were divided into two groups; group A included 43 patients treated with
Rifampin and Trimethoprim plus sodium stibogluconate antimony of them 19 males and 24 females, while group B
included 46 patients(24 males and 22 females) treated with sodium stibogluconate antimony, all were treated and
evaluated weekly. The cure rate in complete response for patients in group A in six week 35(81.39%) and less rate
was in one week 1(2.23%) when as compared with group B which recorded high rate in six week 31(67.39%) while
did not show any response in one week. The highest rate of partial response was observed in the first week
16(37.20%) and then reduced in the third week 12(27.90%) and sixth week 7(16.27%) while the percentage of partial
response in group B was reduced when as compared with group A. The present study recorded that the poor
response of combination therapy in group A was 26(60.46%) in the first week then gradually reduced in third and
sixth week 4(9.30%) and 1(2.32%) respectively while the poor response in group B was high especially in the first
week 45(97.82%) and third week 20(43.47%).The present study showed that using adjunct drug such as Rifampin and
Trimethoprim plus sodium stibogluconate antimony increase the therapeutic activity in treatment of cutaneous
leishmaniasis when as compared with sodium stibogluconate antimony alone.
|
Keyword:
|
Cutaneous Leishmaniasis, Rifampicin and Trimethoprim,Antimony, Therapeutic Efficacy.
|
EOI:
|
-
|
DOI:
|
https://doi.org/10.31838/ijpr/2019.11.02.074
|
Download:
|
Request For Article
|
|
|